Replies to post #3491 on Dendreon Corp fka DNDNQ

[iwfal]

This begs the question, just how beneficial might a fourth booster infusion be? If Dendreon is going to negotiate with the FDA to change the 9902B statistical plan to allow an earlier interim analysis, they should negotiate to allow a booster infusion for all Provenge patients still alive after 6 months.

A change in the clinical protocol (i.e. patients getting an additional shot) is not possible after the first patient is enrolled.